×
About 3,044 results

ALLMedicine™ Hypophosphatemia Center

Research & Reviews  1,369 results

Retrospective analysis of hypophosphatemia rates and other clinical parameters in patie...
https://doi.org/10.1002/erv.2810
European Eating Disorders Review : the Journal of the Eating Disorders Association REFERENCES; Richardson C, Huniewicz P et. al.

Nov 28th, 2020 - To retrospectively assess medical services of a specialist inpatient eating disorders (EDs) unit. We retrospectively evaluated clinical parameters of 288 inpatients classified as 'moderately' or 'significantly' medically compromised between 1 Janu...

Frequent occurrence of hypophosphatemia among multiple myeloma patients treated with el...
https://doi.org/10.1007/s00277-020-04351-5
Annals of Hematology; Regidor B, Swift R et. al.

Nov 25th, 2020 - The purpose of this single-center retrospective study was to determine the incidence of decreased blood phosphorus levels and hypophosphatemia among multiple myeloma (MM) patients treated with elotuzumab. Hypophosphatemia, which is defined as a se...

Diets with high carbohydrate contents were associated with refeeding hypophosphatemia: ...
https://doi.org/10.1002/eat.23416
The International Journal of Eating Disorders REFERENCES; Yamazaki T, Inada S et. al.

Nov 25th, 2020 - Refeeding hypophosphatemia (RH) is a potentially fatal complication in patients with anorexia nervosa (AN), and its dietary preventive strategy is not well established. We aimed to examine the association between carbohydrate content in the diet a...

Vitamin D supplementation improves bone mineralisation independent of dietary phosphate...
https://doi.org/10.1016/j.bone.2020.115767
Bone Barratt KR, Sawyer RK et. al.

Nov 24th, 2020 - The disorder of X-linked hypophosphatemia (XLH), results in the supressed renal production of active 1α,25-dihydroxyvitamin D (1,25(OH)2D) due to elevated fibroblast growth factor-23 (FGF23) levels. While adequate 25(OH)D levels are generally asso...

Improving the safety of intravenous iron treatments for patients with chronic kidney di...
https://doi.org/10.1080/14740338.2021.1853098
Expert Opinion on Drug Safety; Kassianides X, Hazara AM et. al.

Nov 18th, 2020 - Introduction: Iron-deficiency anemia in chronic kidney disease (CKD) is common and has prognostic, financial, and quality of life implications. Intravenous (IV) iron is a key intervention for optimal management, however, ongoing safety concerns ex...

see more →

Drugs  121 results see all →

Clinicaltrials.gov  1,521 results

Retrospective analysis of hypophosphatemia rates and other clinical parameters in patie...
https://doi.org/10.1002/erv.2810
European Eating Disorders Review : the Journal of the Eating Disorders Association REFERENCES; Richardson C, Huniewicz P et. al.

Nov 28th, 2020 - To retrospectively assess medical services of a specialist inpatient eating disorders (EDs) unit. We retrospectively evaluated clinical parameters of 288 inpatients classified as 'moderately' or 'significantly' medically compromised between 1 Janu...

Frequent occurrence of hypophosphatemia among multiple myeloma patients treated with el...
https://doi.org/10.1007/s00277-020-04351-5
Annals of Hematology; Regidor B, Swift R et. al.

Nov 25th, 2020 - The purpose of this single-center retrospective study was to determine the incidence of decreased blood phosphorus levels and hypophosphatemia among multiple myeloma (MM) patients treated with elotuzumab. Hypophosphatemia, which is defined as a se...

Diets with high carbohydrate contents were associated with refeeding hypophosphatemia: ...
https://doi.org/10.1002/eat.23416
The International Journal of Eating Disorders REFERENCES; Yamazaki T, Inada S et. al.

Nov 25th, 2020 - Refeeding hypophosphatemia (RH) is a potentially fatal complication in patients with anorexia nervosa (AN), and its dietary preventive strategy is not well established. We aimed to examine the association between carbohydrate content in the diet a...

Vitamin D supplementation improves bone mineralisation independent of dietary phosphate...
https://doi.org/10.1016/j.bone.2020.115767
Bone Barratt KR, Sawyer RK et. al.

Nov 24th, 2020 - The disorder of X-linked hypophosphatemia (XLH), results in the supressed renal production of active 1α,25-dihydroxyvitamin D (1,25(OH)2D) due to elevated fibroblast growth factor-23 (FGF23) levels. While adequate 25(OH)D levels are generally asso...

Improving the safety of intravenous iron treatments for patients with chronic kidney di...
https://doi.org/10.1080/14740338.2021.1853098
Expert Opinion on Drug Safety; Kassianides X, Hazara AM et. al.

Nov 18th, 2020 - Introduction: Iron-deficiency anemia in chronic kidney disease (CKD) is common and has prognostic, financial, and quality of life implications. Intravenous (IV) iron is a key intervention for optimal management, however, ongoing safety concerns ex...

see more →

News  33 results

Burosumab Is a 'Game Changer,' Effective in All Subgroups of XLH
https://www.medscape.com/viewarticle/937820

Sep 21st, 2020 - A recently approved agent, burosumab (Crysvita), was better than placebo across a range of efficacy outcomes for 14 predefined subgroups of adults with X-linked hypophosphatemia (XLH), new research shows. The authors analyzed data from the initial...

Burosumab Is a 'Game Changer,' Effective in All Subgroups of XLH
https://www.staging.medscape.com/viewarticle/937820

Sep 21st, 2020 - A recently approved agent, burosumab (Crysvita), was better than placebo across a range of efficacy outcomes for 14 predefined subgroups of adults with X-linked hypophosphatemia (XLH), new research shows. The authors analyzed data from the initial...

Burosumab Shows Sustained Efficacy in Rare Inherited Rickets
https://www.medscape.com/viewarticle/919315

Oct 1st, 2019 - ORLANDO, Florida — Burosumab (Crysvita, Ultragenyx), an anti-FGF23 monoclonal antibody, shows long-term safety and efficacy out to almost 2 years in the treatment of X-linked hypophosphatemia (XLH), a rare, inherited form of rickets, according to ...

2018 FDA-approved new drugs
https://www.mdedge.com/obgyn/article/197634/obstetrics/2018-fda-approved-new-drugs/page/0/1?channel=52

Mar 27th, 2019 - Antilipemic agents Crysvita (burosumab-twza), which has a MW of about 147,000, is a fibroblast growth factor–blocking antibody indicated for the treatment of X-linked hypophosphatemia. In pregnant cynomolgus monkeys, doses slightly higher than the.

FGF23 Inhibitor Effective in Rare Inherited Form of Rickets
https://www.staging.medscape.com/viewarticle/904089

Oct 28th, 2018 - SAN DIEGO — For adults with X-linked hypophosphatemia (XLH), a rare inherited form of rickets, a monthly dose of burosumab (Crysvita, Kyowa Hakko Kirin and Ultragenyx Pharmaceutical) can normalize phosphorous levels and enhance bone mineralization...

see more →